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Insulin resistance is an important risk factor for the development of type 2 diabetes and themetabolic
syndrome. A new study in this issue of Cell Metabolism (Sun et al., 2007) shows that SIRT1, a
mammalian sirtuin homolog and histone deacetylase, can ameliorate insulin resistance by silencing
expression of protein tyrosine phosphatase 1B, a major negative regulator of insulin action.Insulin’s ability to acutely stimulate
glucose uptake and metabolism in
peripheral tissues is essential for nor-
mal glucose homeostasis. Resistance
to the action of insulin is a major path-
ogenic feature of type 2 diabetes and
contributes to the morbidity of obesity.
Over the past half century, consider-
able research efforts have focused on
identifying the insulin signaling path-
ways that may be leveraged to achieve
therapeutic outcomes. In insulin-resis-
tant states, multiple insulin signaling
pathways are impaired due to altered
protein expression or activation of
signaling molecules. In recent years,
several negative regulators of insulin
action that contribute to insulin resis-
tance in obesity and type 2 diabetes
have been identified, including protein
tyrosine phosphatase 1B (PTP1B).
PTP1B is a ubiquitously expressed
phosphatase that regulates several
growth factor signaling pathways
in vivo. PTP1B negatively regulates
insulin action directly, as an insulin re-
ceptor phosphatase (Figure 1), and
indirectly, by promoting adiposity
through negative regulation of leptin
action on body weight and energy
expenditure (Dube and Tremblay,
2005). A modest increase in PTP1B
expression in skeletal muscle is suffi-
cient to cause insulin resistance in
mice (Zabolotny et al., 2004). Con-
versely, PTP1B deficiency ameliorates
insulin resistance and diabetes in mice
heterozygous for insulin receptor (IR)
and insulin receptor substrate-1 (IRS-
1) deficiency (Xue et al., 2007). Thus,
PTP1B is involved in the pathogenesis
of insulin resistance in vivo and is a
potential target for treating metabolic
diseases such as type 2 diabetes. Anew study by Zhai and colleagues
(Sun et al., 2007) now shows that the
sirtuin homolog SIRT1 improves insu-
lin signaling in insulin-resistant states
in part by silencing expression of
PTP1B.
Sirtuins comprise a large gene fam-
ily of ancient origins, with homologs
present from yeast to humans (Michan
and Sinclair, 2007). Most sirtuins are
protein lysine deacetylases, all requir-
ing the cofactor nicotinamide adenine
dinucleotide (NAD+) as a cosubstrate.
They have emerged as prominent
regulators of multiple aspects of cell
survival, stress resistance, and metab-
olism. The first sirtuin, silent informa-
tion regulator 2 (Sir2), was originally
found to promote longevity in yeast.
Subsequent research has identified
seven mammalian Sir2 homologs,
SIRT1–7. SIRT1, 3, and 4 play roles in
regulating glucose homeostasis and/
or energy metabolism. SIRT1, cur-
rently the best studied sirtuin homolog,
is expressed in metabolic tissues in-
cluding liver, skeletal muscle, adipose
tissue, pancreas, and brain, where it
regulates b cell and neuron survival,
hepatic gluconeogenesis, insulin se-
cretion, and adiposity (Yang et al.,
2006). To date, SIRT1 deacetylates
approximately a dozen known sub-
strates, including the transcription
factors forkhead box O (FOXO) 1, 3,
and 4; nuclear factor kB (NF-kB)
subunit p65; and peroxisome prolifer-
ator-activated receptor g (PPARg)
coactivator 1a (PGC-1a). Other impor-
tant substrates of SIRT1 include
histones H1, H3, and H4, with histone
deacetylation causing gene silencing.
Direct SIRT1-promoter interactions
have been described for only a fewCell Metabolismmammalian genes, including PPARg,
aP2, myosin heavy chain, and myoge-
nin. It is conceivable that SIRT1 gene
silencing may be mediated by deacety-
lation of multiple substrates involved in
transcription (Vaquero et al., 2004).
Resveratrol, a natural polyphenolic
compound produced in a variety of
plants in response to stress, is a potent
activator of SIRT1. Although SIRT1
regulates important aspects of glu-
cose metabolism and insulin secretion
in mice, whether SIRT1 or resveratrol
directly affects insulin signaling has
been largely unexplored.
Sun et al. (2007) now demonstrate
a direct regulation of insulin action by
SIRT1 through its actions to control
PTP1B gene expression. In insulin-
resistant cultured cells and mice,
SIRT1 expression is downregulated.
SIRT1 knockdown or inhibition impairs
insulin signaling and insulin-stimulated
glycogen synthesis, whereas SIRT1
overexpression ameliorates existing
insulin resistance and impaired glu-
cose transport in cultured cells. Sun
et al. show that these effects are
mediated in part by silencing PTP1B
expression through histone H3 de-
acetylation. Interestingly, SIRT1 over-
expression in non-insulin-resistant
cells does not affect insulin signaling
or glucose transport or markedly affect
PTP1B expression, suggesting that
SIRT1’s action on insulin signaling
and PTP1B is minimal in insulin-sensi-
tive states. Resveratrol treatment of
muscle, liver, and adipocyte cell lines
enhances insulin signaling and insu-
lin-stimulated glucose uptake under
normal as well as insulin-resistant con-
ditions, implying that resveratrol may
have SIRT1-independent effects on6, October 2007 ª2007 Elsevier Inc. 247
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PreviewsFigure 1. Silencing of PTP1B Gene Expression by SIRT1
Top: SIRT1 downregulation in insulin-resistant states is permissive for PTP1B gene overexpression. Increased PTP1B expression in insulin target
tissues leads to impaired insulin-stimulated insulin receptor phosphorylation, resulting in decreased insulin sensitivity. Factors regulating PTP1B
expression in insulin-sensitive and insulin-resistant states have not been well described. Bottom: SIRT1 activation via resveratrol treatment or
SIRT1 overexpression silences PTP1B gene expression in part through histone H3 deacetylation. Decreased PTP1B expression results in enhanced
insulin-stimulated insulin receptor phosphorylation and insulin signaling, resulting in improved insulin sensitivity. Unknown factors include other
acetylated histones or transcription factors bound to the PTP1B promoter that may additionally be subject to SIRT1 regulation. Abbreviations:
Ins, insulin; IR, insulin receptor: Ac, acetylation; 1B, PTP1B protein.insulin action. Resveratrol treatment
of high-fat-fed mice also normalized
glucose tolerance and insulin sensi-
tivity. Thus, SIRT1 improves insu-
lin sensitivity under insulin-resistant
circumstances by silencing PTP1B
expression at the chromatin level.
This new work raises a number of
interesting questions. The in vivo roles
of PTP1B in specific tissues in regulat-
ing ongoing insulin action and body
weight and the effects of PTP1B over-
expression in causing insulin resis-
tance and obesity have not been fully
elucidated. Furthermore, the impor-
tance of SIRT1 as a regulator of insulin
action in vivo is unknown. Although
Sun et al. (2007) report that SIRT1
and PTP1B expression are recipro-
cally regulated in select tissues of
fasted or high-fat-fed mice, direct evi-
dence of SIRT1’s ability to regulate
PTP1B expression or insulin signaling
in insulin-resistant states in diverse
metabolic tissues is still lacking. How-
ever, SIRT1 is expressed in skeletal248 Cell Metabolism 6, October 2007 ª2muscle, liver, adipose tissue, and pan-
creas, where it may regulate insulin
signaling or PTP1B expression. How
PTP1B expression is regulated is
poorly understood at present. Whether
SIRT1 silences PTP1B expression
through deacetylation of additional
histone or transcription factor sub-
strates in addition to histone H3 has
yet to be determined. Another impor-
tant question requiring further explo-
ration is whether SIRT1 activation in
insulin-resistant states silences other
negative regulators of insulin action.
Also, it is unclear whether SIRT1
activation or resveratrol treatment in
animals lowers PTP1B expression in
multiple cell types and, if so, whether
this may have effects beyond regulat-
ing glucose homeostasis. PTP1B reg-
ulates a number of other growth factor
signaling pathways, and PTP1B’s
role in cancer development remains
complex and ill defined (Dube and
Tremblay, 2005). PTP1B deficiency
prevents breast cancer development007 Elsevier Inc.in animal models (Tonks and
Muthuswamy, 2007), whereas PTP1B
deficiency in tumor suppressor p53-
deficient mice decreases survival rate
and increases susceptibility toward
developing B cell lymphomas, sug-
gesting that PTP1B expression is an
important determinant of tumor la-
tency under some conditions (Dube
et al., 2005). This may be an important
issue, given that SIRT1 deactivates
p53 (Michan and Sinclair, 2007).
PTP1B also plays an important role
in myeloid differentiation and macro-
phage activation in vivo, raising con-
cerns that SIRT1 silencing of PTP1B
could alter immune function (Dube
and Tremblay, 2005).
Lastly, PTP1B deficiency in neurons
promotes leanness, prevents diet-
induced obesity, and enhances insulin
sensitivity (Bence et al., 2006). Simi-
larly, high-dose resveratrol treatment
protects mice from diet-induced obe-
sity (Lagouge et al., 2006). Resvera-
trol crosses the blood-brain barrier
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SIRT1 activation plays important roles
in the regulation of neuron survival in
ischemia and other neurodegenerative
conditions (Michan and Sinclair, 2007).
The current work by Sun et al. (2007),
together with previous studies, raises
the possibility that resveratrol’s effect
on body weight and insulin sensitivity
may be partly due to SIRT1 silencing
of neuronal PTP1B expression. Further
research is needed to delineate the
effects of resveratrol and SIRT1 on
insulin signaling in peripheral tissues
and hypothalamus to understand how
these important molecules regulate
insulin sensitivity and/or body weight
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Fatty acid synthase (FAS) is a key
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Obesity rates are on the rise through-
out the world. The most serious public
health consequence of obesity is the
increasing rate of type 2 diabetes
mellitus. Weight loss dramatically
improves type 2 diabetes mellitus, but
we are still far from having efficient
and safe tools at hand to achieve
weight loss in patients. Up to now,
many genes have been identified that
make mice susceptible to diet-induced
obesity, yet the number of molecular
targets whose pharmacological inhibi-
tion induces marked weight loss in
obesity without undesirable side ef-
fects is very low. A recent paper (Chak-
ravarthy et al., 2007) demonstrates that
FAS in hypothalamic neurons repre-REFERENCES
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Consider the hypothalamus to be
the command center that governs not
only appetite but also glucose and
lipid metabolism in peripheral organs
like liver, adipose tissue, and muscle.
How are cues from the periphery
sensed by the hypothalamus to assess
the energy state of the organism, and
how are these integrated to control
energy homeostasis? In recent years,
it has become clear that the hypothal-
amus assimilates neuronal, hormonal,
and nutrient signals. The hypothala-
mus then integrates these signals to
regulate food intake and energy
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study (Chakravarthy et al., 2007)
produces hypophagic, lean mice
f the effects of FAS on energy
metabolism, presumably via the auto-
nomic nervous system. The serendipi-
tous discovery that the FAS inhibitor
C75, originally developed as an anti-
neoplastic agent, markedly reduces
body weight in mice pointed to FAS
as a potential integrator of hormonal
and nutrient signals within the hypo-
thalamus (Loftus et al., 2000). From
the outset, there were good indica-
tions that the anorectic effects of C75
were centrally mediated, as intracere-
broventricular administration of C75
replicated the anorectic effects of
systemic administration of C75. These
findings triggered a reconsideration
of the role of fatty acid metabolism in
energy homeostasis and advanced
6, October 2007 ª2007 Elsevier Inc. 249
